Context Therapeutics Inc.
CNTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CNTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CNTX
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing bispecific antibodies for solid tumors, with lead programs CTIM-76 and CT-95 in Phase 1 dose escalation and a Nectin-4 bispecific candidate CT-202 entering first-in-human trials.
Key risk: No approved products
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 4 clinical trials · 1 catalyst for Context Therapeutics Inc..
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing bispecific antibodies for solid tumors, with lead programs CTIM-76 and CT-95 in Phase 1 dose escalation and a Nectin-4 bispecific candidate CT-202 entering first-in-human trials.
- Cash and cash equivalents were $43.0M as of 2026-06-30 [sec].
- Net loss was -$14.6M for the quarter ended 2026-06-30 [sec].
- Shareholders' equity was $60.5M as of 2026-06-30 [sec].
- Lead candidates CTIM-76 and CT-95 are in Phase 1a dose escalation [sec_mda · as of 2026-03-23].
- CT-202, a Nectin-4 directed bispecific antibody, is expected to begin a Phase 1a/1b first-in-human study in 2026-09-01 [catalyst].
What works
- Cash runway extends into mid-2027 based on December 2025 estimates, supporting ongoing Phase 1 trials and CT-202 initiation [sec_mda · as of 2026-03-23].
- Pipeline includes three distinct bispecific programs targeting solid tumors, providing multiple shots on goal [sec_mda · as of 2026-03-23].
- CT-202 is a Nectin-4 bispecific antibody, a validated oncology target with potential for differentiated activity [catalyst].
What to weigh
- Company has no approved products and has incurred significant operating losses; accumulated deficit was $130.9M as of December 31, 2025 [sec_mda · as of 2026-03-23].
- All candidates are in early clinical or preclinical stages, with no efficacy data yet available [sec_mda · as of 2026-03-23].
- Substantial additional financing will be needed to complete development and commercialization; lack of liquidity could materially affect prospects [sec_mda · as of 2025-11-05].
From the filings
Quoted directly from source documents.
Cash position and runway
“As of December 31, 2025, we had $66.0 million in cash and cash equivalents and an accumulated deficit of $130.9 million. We expect our cash and cash equivalents at December 31, 2025 to fund the estimated duration of the Phase 1a dose escalation portions of our CTIM-76 and CT-95 trials, the estimated expenses to initiate patient enrollment in a first-in-human trial for CT-202, as well as our operations into mid-2027.”
SEC MD&A · March 23, 2026
Need for additional financing
“If the Company is unable to obtain additional financing, the lack of liquidity could have a material adverse effect on the Company's future prospects. We will need to raise substan”
SEC MD&A · November 5, 2025
Catalyst timeline
- 2026-09-01 · Phase 1 Start for CT-202 — A Phase 1a/1b, first-in-human study of CT-202, a Nectin-4 directed bispecific antibody, is expected to begin enrollment.
Risks & what to watch (4)›
Key risks
- No approved products — All candidates are in early development; no revenue from product sales [sec_mda · as of 2026-03-23].
- Cash runway dependency — Cash of $43.0M as of 2026-06-30 may not be sufficient if trials extend or costs rise [sec].
- Clinical failure risk — Phase 1 dose escalation trials for CTIM-76 and CT-95 have no reported efficacy data [sec_mda · as of 2026-03-23].
- Financing uncertainty — Company will need substantial additional capital; lack of liquidity could materially harm prospects [sec_mda · as of 2025-11-05].
What to watch
- Initiation of Phase 1a/1b trial for CT-202 (Nectin-4 bispecific) expected around 2026-09-01 [catalyst].
- Dose escalation data from CTIM-76 and CT-95 Phase 1 trials [sec_mda · as of 2026-03-23].
- Cash burn rate and any future financing or partnership announcements [sec_mda · as of 2026-03-23].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Context Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Context Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
18.7 months
D/E 0.21 · 0% dilution
Lead: Phase 1
3 candidates
1 upcoming, next in ~2d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
56
Total value held
$150.8M
| Holder | Shares | Value |
|---|---|---|
| mpm bioimpact llc | 10,679,391 | $28.0M |
| avidity partners management lp | 9,996,534 | $24.9M |
| deep track capital, lp | 7,419,355 | $19.4M |
| vanguard capital management llc | 6,863,906 | $18.0M |
| franklin resources inc | 3,803,338 | $10.0M |
| marshall wace, llp | 2,948,441 | $7.7M |
| tcg crossover management, llc | 2,682,696 | $7.0M |
| great point partners llc | 2,238,496 | $5.9M |
| millennium management llc | 1,424,374 | $3.7M |
| squadron capital management llc | 1,100,000 | $2.9M |
Showing top 10 of 56 institutional holders of Context Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.1%
- Days to cover
- 1.0
- Shares short
- 898,683
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CNTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Context Therapeutics Inc.?
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing bispecific antibodies for solid tumors, with lead programs CTIM-76 and CT-95 in Phase 1 dose escalation and a Nectin-4 bispecific candidate CT-202 entering first-in-human trials.
What is Context Therapeutics Inc.'s lead drug candidate?
Context Therapeutics Inc.'s most advanced tracked candidate is CT-202 (Phase 1) for Triple Negative Breast Cancer (TNBC).
What is Context Therapeutics Inc.'s next catalyst?
Context Therapeutics Inc.'s next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Phase 1a/1b, First Time in Human Study of CT-202, A Nectin-4 Directed Bispecific Antibody, in Part" — expected September 1, 2026.
Who is the CEO of Context Therapeutics Inc.?
Mr. Martin A. Lehr is the chief executive officer of Context Therapeutics Inc. (CNTX).
Where is Context Therapeutics Inc. headquartered?
Context Therapeutics Inc. (CNTX) is headquartered in Philadelphia, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.